NINLARO, with its active ingredient ixazomib, is an oral medication used in the treatment of multiple myeloma, a type of cancer that arises from plasma cells in the bone marrow. As a proteasome inhibitor, NINLARO works by blocking the action of proteasomes, complex enzymes within cells that break down proteins. This action disrupts the controlled degradation of proteins necessary for cell cycle progression and survival, particularly affecting cancer cells more than normal cells. Typically, NINLARO is used in combination with other medications, such as lenalidomide and dexamethasone, to enhance its efficacy. This combination therapy is aimed at patients who have received at least one prior treatment for their multiple myeloma, offering a convenient, once-a-week oral dosing regimen that allows for treatment continuity and patient comfort.